SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced positive topline results from the DARE-BVFREE Phase 3 ...
DARE-BV1 is an investigational, proprietary thermosetting hydrogel formulation of clindamycin phosphate 2% for one-time vaginal administration in patients diagnosed with bacterial vaginosis SAN DIEGO, ...
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing ...
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) accepted for ...
Daré, which focuses on women's health, said Monday that its BV1 — a thermosetting hydrogel containing clindamycin phosphate 2% — has been given the Qualified Infectious Disease Product, or QIDP, ...
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a ...
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results